- Global Pharma News & Resources

AlzeCure presents new data at Alzheimer’s conference AD/PD on the potential disease-modifying effect of NeuroRestore ACD856

AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company's presentation at the Alzheimer's conference AD/PD 2023 is now available in its entirety on the company's website. The presentation contains new preclinical data with the company's leading clinical drug candidate NeuroRestore ACD856, which is being developed with a focus on Alzheimer's disease.

”These new data with ACD856 further demonstrate that the substance has potential disease-modifying properties, both in terms of protecting nerve cells from damage but also positive long-term effects on nerve cell function”, said Johan Sandin, CSO at AlzeCure and co-author of the abstract.

The abstract, titled Effects on neuroprotection and neuroplasticity by the clinical compound ACD856, a novel positive modulator of Trk-receptors from the NeuroRestore® platform, was presented by Johan Sandin, CSO, contains new preclinical results with ACD856, the leading drug candidate in the NeuroRestore platform.

The results from the preclinical studies showed that ACD856 has a neuroprotective effect and increases the amount of SNAP25, a protein that is linked to the contact surfaces between nerve cells, so-called synapses, which disappear and lead to the classical symptoms of Alzheimer's disease. Furthermore, positive, persistent long-term effects were also observed, suggesting effects on neuronal plasticity, a phenomenon that plays an important role in cognitive function.

ACD856, which is a positive modulator of both NGF/TrkA- and BDNF/TrkB-mediated signaling, has been shown in previous preclinical studies to improve learning and memory and is being developed primarily for the treatment of Alzheimer's disease. The drug candidate recently completed phase I clinical trials where both good safety and tolerability were observed in humans, and that ACD856 crossed the blood-brain barrier and activated regions of the brain central to both cognition and depression treatment.

”With the positive clinical results we previously obtained with ACD856, as well as the new preclinical results that further support a disease-modifying effect, we have a very promising drug candidate in our research portfolio, which gives us increased opportunities, including in terms of business development", said Martin Jönsson, CEO of AlzeCure.

The other co-authors of the abstract are Sanja Juric, Cristina Parrado-Fernández, Nather Madjid, Gunnar Nordvall, Maria Backlund, Märta Dahlström and Pontus Forsell.

The poster and the abstract are available on AlzeCure's website (

Editor Details

Last Updated: 30-Mar-2023